Roivant Sciences, Inc.
NEWS
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
Urovant Sciences, a Vivek Ramaswamy company under the Roivant umbrella, has filed for an initial public offering (IPO) to raise $150 million. It will list on Nasdaq under the UROV symbol.
A number of companies are making the transition from the third quarter to the fourth quarter with licensing deals to bolster their pipelines. Here’s a look at just a few of them.
Three of Vivek Ramaswamy’s companies reported activity today including corporate changes, a licensed therapy and investment of $100 million.
Fresh off its first Pipeline Day last week, Vivek Ramaswamy’s Roivant Sciences is taking aim at breaking into the Chinese market. Roivant has launched another company called Sinovant Sciences.
Enzyvant Sciences, one of Vivek Ramaswamy’s numerous ‘Vant’ companies, filed a rolling submission of a Biologics License Application (BLA) for RVT-802 with the U.S. Food and Drug Administration for the treatment of DiGeorge Anomaly (cDGA), an immunodeficiency disease that impacts infants.
Changes continue coming to Vivek Ramaswamy’s Roivant Sciences following a June shakeup that saw a 10 percent cut in employment and the restructuring of its business operations.
Roivant Sciences, Vivek Ramaswamy’s umbrella company for his family of “Vants,” announced major restructuring that includes a cut of 10 percent of staff and reshuffling of leadership.
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
JOBS
IN THE PRESS